FRTX
Price
$0.66
Change
-$0.00 (-0.00%)
Updated
Jan 16 closing price
Capitalization
3.94M
38 days until earnings call
XRTX
Price
$1.00
Change
-$0.06 (-5.66%)
Updated
Jan 17 closing price
Capitalization
3.27M
Ad is loading...

FRTX vs XRTX

Header iconFRTX vs XRTX Comparison
Open Charts FRTX vs XRTXBanner chart's image
Fresh Tracks Therapeutics
Price$0.66
Change-$0.00 (-0.00%)
Volume$617
Capitalization3.94M
XORTX Therapeutics
Price$1.00
Change-$0.06 (-5.66%)
Volume$39.36K
Capitalization3.27M
FRTX vs XRTX Comparison Chart
Loading...
XRTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
FRTX vs. XRTX commentary
Jan 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FRTX is a Hold and XRTX is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 19, 2025
Stock price -- (FRTX: $0.66 vs. XRTX: $1.00)
Brand notoriety: FRTX and XRTX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: FRTX: 28% vs. XRTX: 29%
Market capitalization -- FRTX: $3.94M vs. XRTX: $3.27M
FRTX [@Biotechnology] is valued at $3.94M. XRTX’s [@Biotechnology] market capitalization is $3.27M. The market cap for tickers in the [@Biotechnology] industry ranges from $352.92B to $0. The average market capitalization across the [@Biotechnology] industry is $2.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

FRTX’s FA Score shows that 1 FA rating(s) are green whileXRTX’s FA Score has 0 green FA rating(s).

  • FRTX’s FA Score: 1 green, 4 red.
  • XRTX’s FA Score: 0 green, 5 red.
According to our system of comparison, both FRTX and XRTX are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

XRTX’s TA Score shows that 4 TA indicator(s) are bullish.

  • XRTX’s TA Score: 4 bullish, 3 bearish.

Price Growth

FRTX (@Biotechnology) experienced а -7.15% price change this week, while XRTX (@Biotechnology) price change was -20.79% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.44%. For the same industry, the average monthly price growth was +2.65%, and the average quarterly price growth was -1.89%.

Reported Earning Dates

FRTX is expected to report earnings on Feb 26, 2025.

XRTX is expected to report earnings on May 01, 2024.

Industries' Descriptions

@Biotechnology (-1.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
FRTX($3.94M) has a higher market cap than XRTX($3.27M). FRTX YTD gains are higher at: -10.811 vs. XRTX (-11.641). XRTX has more cash in the bank: 2.3M vs. FRTX (251K). FRTX has less debt than XRTX: FRTX (0) vs XRTX (61.5K).
FRTXXRTXFRTX / XRTX
Capitalization3.94M3.27M121%
EBITDAN/A-4.33M-
Gain YTD-10.811-11.64193%
P/E RatioN/A8.32-
RevenueN/A0-
Total Cash251K2.3M11%
Total Debt061.5K-
FUNDAMENTALS RATINGS
FRTX vs XRTX: Fundamental Ratings
FRTX
XRTX
OUTLOOK RATING
1..100
8894
VALUATION
overvalued / fair valued / undervalued
1..100
10
Undervalued
45
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9894
PRICE GROWTH RATING
1..100
8493
P/E GROWTH RATING
1..100
10080
SEASONALITY SCORE
1..100
65n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

FRTX's Valuation (10) in the null industry is somewhat better than the same rating for XRTX (45). This means that FRTX’s stock grew somewhat faster than XRTX’s over the last 12 months.

FRTX's Profit vs Risk Rating (100) in the null industry is in the same range as XRTX (100). This means that FRTX’s stock grew similarly to XRTX’s over the last 12 months.

XRTX's SMR Rating (94) in the null industry is in the same range as FRTX (98). This means that XRTX’s stock grew similarly to FRTX’s over the last 12 months.

FRTX's Price Growth Rating (84) in the null industry is in the same range as XRTX (93). This means that FRTX’s stock grew similarly to XRTX’s over the last 12 months.

XRTX's P/E Growth Rating (80) in the null industry is in the same range as FRTX (100). This means that XRTX’s stock grew similarly to FRTX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
XRTX
RSI
ODDS (%)
N/A
Stochastic
ODDS (%)
Bullish Trend 6 days ago
90%
Momentum
ODDS (%)
Bullish Trend 6 days ago
88%
MACD
ODDS (%)
N/A
TrendWeek
ODDS (%)
Bearish Trend 6 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 6 days ago
88%
Advances
ODDS (%)
Bullish Trend 14 days ago
85%
Declines
ODDS (%)
Bearish Trend 7 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 6 days ago
81%
Aroon
ODDS (%)
Bearish Trend 6 days ago
90%
View a ticker or compare two or three
Ad is loading...
XRTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TSLA426.5012.68
+3.06%
Tesla
SPY597.585.94
+1.00%
SPDR® S&P 500® ETF Trust
AAPL229.981.72
+0.75%
Apple
BTC.X104408.070000-53.968750
-0.05%
Bitcoin cryptocurrency
GME27.51-0.21
-0.76%
GameStop Corp

FRTX and

Correlation & Price change

A.I.dvisor tells us that FRTX and XRTX have been poorly correlated (+26% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that FRTX and XRTX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FRTX
1D Price
Change %
FRTX100%
N/A
XRTX - FRTX
26%
Poorly correlated
-5.84%
IMMP - FRTX
25%
Poorly correlated
-0.52%
DRTS - FRTX
22%
Poorly correlated
+0.26%
ESLA - FRTX
21%
Poorly correlated
+0.68%
LSTA - FRTX
16%
Poorly correlated
-0.27%
More

XRTX and

Correlation & Price change

A.I.dvisor indicates that over the last year, XRTX has been loosely correlated with BCDA. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if XRTX jumps, then BCDA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XRTX
1D Price
Change %
XRTX100%
-5.84%
BCDA - XRTX
36%
Loosely correlated
+2.78%
TRML - XRTX
30%
Poorly correlated
+3.87%
FRTX - XRTX
26%
Poorly correlated
N/A
BYSI - XRTX
26%
Poorly correlated
+2.38%
PHMMF - XRTX
23%
Poorly correlated
N/A
More